Latest News
Chinese inactivated COVID-19 vaccine starts phase-3 clinical trials in Argentina
Last Updated: 2020-08-23 09:41 | Xinhua
 Save  Print   E-mail
An inactivated COVID-19 vaccine developed by China has started phase-3 clinical trials in Argentina, according to its developer China National Biotec Group (CNBG), which is affiliated to Sinopharm.
 
The launch ceremony of the phase-3 clinical trials was held in Beijing Friday after the CNBG obtained the certificate of approval for the process.
 
This is an achievement brought about by CNBG's international cooperation in a bid to develop a COVID-19 vaccine. The inactivated vaccine received approval for phase-3 clinical trials in the United Arab Emirates on June 23, and in Peru and Morocco on Thursday.
 
The CNBG will work together with a company in Argentina to promote research and development related to the inactivated vaccine.
 
Liu Jingzhen, chairman of Sinopharm, said the phase-3 clinical trials will help fight the epidemic and contribute to the building of a community of health for all. 
 

(Editor:Fu Bo)

Share to 
0
Related Articles:
BACK TO TOP
  • Sports
  • Soccer
  • Basketball
  • Tennis
  • Formula One
  • Athletics
  • Others
  • Entertainment
  • Celebrity
  • Movie & TV
  • Music
  • Theater & Arts
  • Fashion
  • Beauty Pageant
Edition:
Link:    
About CE.cn | About the Economic Daily | Contact us
Copyright 2003-2024 China Economic Net. All right reserved
Chinese inactivated COVID-19 vaccine starts phase-3 clinical trials in Argentina
Source:Xinhua | 2020-08-23 09:41
Share to 
0